JNJ

Johnson & Johnson 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

This report covers the fiscal year ended December 29, 2024. Johnson & Johnson (JNJ) operates as a holding company with approximately 138,100 employees worldwide. The company is organized into two primary reportable segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The Consumer Health business was fully separated and divested in 2023 (Kenvue), with results reported as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Worldwide sales increased 4.3% to $88.8 billion, driven by a 5.9% volume increase offset by a 1.6% negative currency impact. U.S. sales grew 8.3%, while international sales declined 0.5%.
• Segment Performance:
  • Innovative Medicine: Sales rose 4.0% to $57.0 billion. Growth was led by Oncology (+17.7%) and Pulmonary Hypertension (+12.3%), partially offset by declines in Immunology (-1.2%) and Infectious Diseases (-23.1%) due to the normalization of COVID-19 vaccine sales.
  • MedTech: Sales increased 4.8% to $31.9 billion, driven by the Cardiovascular franchise (+21.4%) following the acquisition of Shockwave Medical.
• Profitability: Earnings before tax increased to $16.7 billion (18.8% margin) from $15.1 billion (17.7% margin). The effective tax rate increased to 15.7% due to higher income in high-tax jurisdictions and the impact of Pillar Two legislation.
• Acquisitions: The company completed the acquisition of Shockwave Medical ($13.1 billion enterprise value) and Ambrx Biopharma ($2.0 billion), alongside asset acquisitions for V-Wave and Yellow Jersey.

Guidance, Outlook, and Risks

Management Commentary: Management highlighted a commitment to innovation, with $17.2 billion invested in R&D (19.4% of sales). New products introduced in the last five years accounted for approximately 25% of 2024 sales. The company increased its dividend for the 62nd consecutive year to $4.91 per share in 2024.

Key Risks and Contingencies:

• Talc Litigation: The company maintains a reserve of approximately $11.6 billion (present value) for talc-related claims. In September 2024, a subsidiary (Red River Talc) filed for Chapter 11 bankruptcy to facilitate a "prepackaged" settlement plan valued at approximately $8.0 billion nominal ($6.475 billion present value) to resolve ovarian cancer claims. A hearing on plan confirmation is scheduled for February 2025.
• Patent Expirations: Significant revenue exposure exists for STELARA (11.7% of 2024 sales) and DARZALEX (13.1% of 2024 sales). Biosimilar launches for STELARA are expected in 2025, which will impact sales.
• Regulatory Environment: The Inflation Reduction Act (IRA) poses pricing risks, with government price negotiations for certain drugs (including XARELTO and STELARA) expected to begin in 2026. The company is litigating the constitutionality of the IRA's negotiation program.
• Geopolitical Risks: Ongoing conflicts in the Middle East and Russia-Ukraine, as well as trade tensions with China, present supply chain and currency risks.

Investor Verification Checklist

• Talc Settlement Progress: Monitor the confirmation hearing of the Red River Talc bankruptcy plan in February 2025 and any potential appeals or changes to the $11.6 billion reserve.
• STELARA Biosimilar Launch: Verify the timing and market impact of biosimilar launches in the U.S. and Europe expected in 2025.
• IRA Implementation: Track the finalization of the Centers for Medicare & Medicaid Services (CMS) price negotiation methodology and the outcome of J&J's litigation challenging the IRA.
• Acquisition Integration: Assess the financial integration and synergy realization of the Shockwave Medical and Ambrx Biopharma acquisitions.
• Debt Maturity Profile: Review the $36.6 billion debt balance, noting the issuance of new senior unsecured notes in 2024 to fund acquisitions.